58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2024-10-01 DOI:10.1016/j.ejca.2024.114585

A. Hollebecque, E. Dotan, C.Y.A. Liao, D. Roda, E. Fontana, H. Babiker, R.D. Kim, D.Y. Oh, F. Ghiringhelli, I. Moreno, J. Liu, V. Subbiah, A. Varkaris, M.J. Borad, P.A. Cassier, A. Deary, F.T. Ramirez, F. Ricard, K.Y. Jen, A.M. Schram

引用次数: 0

查看原文本刊更多论文

58 (PB046)：高选择性表皮生长因子受体2（FGFR2）融合或重排（f/r）晚期实体瘤患者（pts）中利拉伐替尼（lirafugratinib）的肿瘤诊断疗效和安全性：ReFocus研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.